IL6 and rheumatoid arthritis: Remarkably, BM-MSCs possess the capability to inhibit TNF-α production (reported here) and, simultaneously, impair IL-6 expression and Th1 and Th17 cells’ function in healthy individuals [20] and RA patients [21].